$Relmada Therapeutics (RLMD.US)$ $Denali Therapeutics (DNLI.US)$ $Tango Therapeutics (TNGX.US)$ $Goldman Sachs (GS.US)$ Goldman Sachs announced the latest list of potential acquisitions in the biopharmaceutical sector. Relmada, Denali and Tango have the most potential acquisition opportunities of the nine newly listed companies, Goldman sachs said. Relmada could trade at $115 a share, a 512% premium to its current price; Denali could trade at $166 a share, a 283% premium to its current price; Tango is likely to trade at $43.40 a share, a 295% premium to its current share price. The health care company with the biggest premium of the 24 companies listed is $uniQure NV (QURE.US)$, which Goldman estimates could trade at $174 a share, a 516% premium to its current price.

$JD.com (JD.US)$ $Tesla (TSLA.US)$ $PDD Holdings (PDD.US)$ $Grab Holdings (GRAB.US)$ $XPeng (XPEV.US)$
The things that i shared in my youtube are an accumination of more than 10 plus years of experience. It is not something that can be googled unlike fake guru that sells you stuff found on the internet for thousands of dollars. I have gone through the 2008 and 2020 crisis and my portfolio doubled during each crisis.
You can now learn it for free.
https://youtu.be/z4U4EwXMXVQ​

$SoFi Technologies (SOFI.US)$ It's sad that some of SoFi's traders who are also customers are getting absolutely destroyed on options and margin. Might leave a bad taste in their mouth to do business with a company they lost so much money on. Crazy thing is, Noto doesn't even want to offer options and margin because he wants to help you get your money right.

Inflation leads to a slowing economy.  Companies with record profits will cut heads and compensation to expand margins, maybe it's companies this time that will drive the next downturn.
$Advanced Micro Devices (AMD.US)$ $Rivian Automotive (RIVN.US)$ $Tesla (TSLA.US)$ $Disney (DIS.US)$ $Netflix (NFLX.US)$

According to wind statistics, as of December 6, 63 stocks in the $S&P 500 Index (.SPX.US)$ S & P 500 information technology sector had achieved positive returns, accounting for more than half. Among them, $NVIDIA (NVDA.US)$won the first place in the market value of 100 billion players with an increase of more than 130%, and reached a record high of 55 times in the year! The same chip stocks of $Applied Materials (AMAT.US)$ also performed well, followed by an annual increase of nearly 72%.
Generally speaking, in 2021, although US stocks continued the upward trend of the bull market, the market structure is completely different from that in 2020.
At the beginning of the year, US technology stocks showed signs of weakness. Under the background of economic recovery, traditional value stocks and cyclical stocks once led the rise. But soon, driven by the sharp rise in the company's performance, large technology stocks continued to become the main driving force, while small and medium-sized technology growth stocks opened a downward market and took the lead in entering the technical bear market.
By the middle of 2021, the trend differentiation within technology stocks will be more obvious. On the one hand, large technology stocks rose in a "forced air" manner, driving the index to new highs, while growth stocks ushered in a sharp correction, including many star stocks that made great achievements last year, such as zillow, roku, pinterest, zoom, etc. Therefore, wood's Ark fund is also sinking rapidly and has become the main target of short selling in the market.
The reason is also very simple. The words and deeds of the Federal Reserve have always been the wind vane on the way forward for US stocks. In 2021, the sensitivity to the interest rate market led to the differentiation of science and technology stocks, and the science and technology giants whose immediate performance maintained a high growth momentum are still favored by capital.
In recent years, the five giants FFANG（ $Meta Platforms (FB.US)$ $Apple (AAPL.US)$ $Amazon (AMZN.US)$ $Netflix (NFLX.US)$ $Alphabet-A (GOOGL.US)$） known to the market are also becoming the six MAMATA ( $Microsoft (MSFT.US)$ $Apple (AAPL.US)$ $Meta Platforms (FB.US)$ $Amazon (AMZN.US)$ $Tesla (TSLA.US)$ $Alphabet-A (GOOGL.US)$ ). The development of the technology industry itself is a process of continuous innovation and subversion, and the speed of change often exceeds most people's expectations.
Which technology stocks will be bullish in 2022? Welcome to the passionate discussion in the comment area~
$Intuit (INTU.US)$ $Advanced Micro Devices (AMD.US)$ $Accenture (ACN.US)$ $Oracle (ORCL.US)$ $Broadcom (AVGO.US)$ $Cisco (CSCO.US)$

$DocuSign (DOCU.US)$ Yamato: Decrease the target price of DocuSign (DOCU.O) from US$325 to US$189.
$Eli Lilly and Co (LLY.US)$ Wells Fargo Bank: Give Lilly (LLY.N) a wait-and-see initial rating with a target price of US$270
$CVS Health (CVS.US)$ Mizuho: Raise the target price of CVS Health (CVS.N) from US$105 to US$110.

$Marvell Technology (MRVL.US)$
Chipmakers are firing on all cylinders this year, and Marvell Technology has enjoyed a nice rally. From May to November, shares of the Wilmington, Delaware-based semiconductor company climbed a whopping 60%.
But that could just be a start. Marvell reported third quarter earnings Dec. 2. In the following trading session, the stock shot up 17.7%.
Revenue for the quarter grew 61% year-over-year to $1.21 billion. Adjusted earnings per share improved 72% from a year ago to 43 cents.
A nice post-earnings pop brought Marvell’s share price to about $84. But Goldman Sachs sees more upside ahead.
The bank upgraded Marvell from “neutral” to “buy” on Dec. 3 and raised its price target to $95.